New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...

Hypertrophic cardiomyopathy (HCM) causes heart muscle thickening that may lead to obstructed blood flow. Symptoms include ...

A new study has uncovered that a gene variant common in Oceanian communities was misclassified as a potential cause of heart ...

Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% by 2030. Mr. Shah Coherent Market Insights Pvt. Ltd.

Both smoking and hypertrophic cardiomyopathy (HCM) increase your risk of negative cardiovascular outcomes. By quitting cigarettes, you can support your HCM management plan. Hypertrophic ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM), ...

Danon disease is a rare but serious cardiomyopathy that drastically reduces life expectancy. Male patients infrequently live ...

Researchers at St. Jude Children’s Research Hospital identified a panel of 27 serum proteins that accurately predicted ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

The FDA has granted Priority Review to the BLA for deramiocel (CAP-1002) for the treatment of Duchenne muscular dystrophy cardiomyopathy.